Europe Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others), By End User, By Country and Growth Forecast, 2022 - 2028

The Europe Proton Therapy Market is expected to witness market growth of 12.2% CAGR during the forecast period (2022-2028).

Proton therapy may be chosen by doctors when deciding whether to use photon or proton therapy to treat a tumor if it is crucial to give a higher radiation dose to targeted tissues while dramatically reducing radiation to surrounding organs at risk. In the Model Policy for Proton Beam Treatment of the American Society for Proton therapy, proton radiation therapy is justified when it can benefit the patient while protecting nearby normal tissues and cannot be achieved properly by photon radiation.

Proton radiation therapy is frequently combined with chemotherapy and/or surgery to treat cancer, similar to photon radiation therapy. Isochronous cyclotrons are used in the majority of installed proton treatment systems. Cyclotrons are thought to be reliable, easy to use, and small, especially when superconducting magnets are used. It is also possible to employ synchrotrons, with the benefit of simpler production at various energies. As size and cost restrictions are overcome, linear accelerators - used in photon radiation therapy - are becoming commercially available.

Early identification of breast cancer is frequent in Europe, many women might be qualified for breast-saving surgery (BCT). As cases of breast cancer, lung cancer, liver cancer, and prostate cancer rise, there will be a rising demand for a range of cancer treatments and solutions throughout the region throughout the projection period. This will drive the development and acceptance of the proton therapy market in this area.

The Germany market dominated the Europe Proton Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $62,652.5 Thousands by 2028. The UK market is expected to witness a CAGR of 11.3% during (2022 - 2028). Additionally, The France market is anticipated to witness a CAGR of 13.1% during (2022 - 2028).

Based on Product Type, the market is segmented into Accelerator, Beam Delivery System, Beam Transport System, Nozzle & Image Viewers and Patient Positioning System. Based on Indication, the market is segmented into CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others. Based on End User, the market is segmented into Hospitals, Proton Therapy Centers and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation and Optivus Proton Therapy, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Product Type

• Accelerator
• Beam Delivery System
• Beam Transport System
• Nozzle & Image Viewers
• Patient Positioning System

By Indication

• CNS Cancer
• Prostate Cancer
• Head & Neck Cancer
• Breast Cancer
• Others

By End User

• Hospitals
• Proton Therapy Centers
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Toshiba Corporation
• Siemens Healthineers AG (Siemens AG)
• Ion Beam Applications SA
• Hitachi, Ltd.
• Mirion Technologies, Inc.
• Mevion Medical Systems, Inc.
• Provision Healthcare
• Sumitomo Corporation
• Optivus Proton Therapy, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free